LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
复制标题
LT-171-861是一种新型FLT3抑制剂，在治疗FLT3突变型急性髓系白血病方面表现出优异的临床前疗效
作者：
Yu Z;Du J;Hui H;Kan S;Huo T;Zhao K;Wu T;Guo Q;Lu N
Rationale: Acute myeloid leukemia (AML) is a common type of haematological malignancy. Several studies have shown that neoplasia in AML is enhanced by tyrosine kinase pathways. Recently, given that aberrant activation of Fms-like tyrosine receptor kinase 3 (FLT3) acts as a critical survival signal for cancer cells in 20‒30% patients with AML, inhibition of FLT3 may be a potential therapeutic strategy. Therefore, we identified LT-171-861, a novel kinase inhibitor with remarkable inhibitory activity against FLT3, in preclinical models of AML. Methods: We determined the inhibitory effects of LT-171-861 in vitro using AML cell lines and transformed BaF3 cells. Target engagement assays were used to verify the interaction between LT-171-861 and FLT3. Finally, a subcutaneous model and a bone marrow engrafted model were used to evaluate the antitumor effects of LT‑171‑861 in vivo. Results: Our data demonstrated that LT-171-861 had high affinity for FLT3 protein. We also showed that LT-171-861 had an inhibitory effect on FLT3 mutants in cellular assays. Moreover, LT-171-861 had a growth-inhibitory effect on human AML cell lines harboring FLT3 internal tandem duplications (FLT3-ITD) such as FLT3-D835Y, FLT3‑ITD-N676D, FLT3-ITD-D835Y, FLT3-ITD-F691L, FLT3-ITD-Y842C and AML blasts from patients with FLT3-ITD. Furthermore, LT-171-861 showed potent antileukemic efficacy against AML cells. We also show the efficacy of LT‑171-861 in a subcutaneous implantation model and a bone marrow engrafted model in vivo, where administration of LT-171-861 led to almost complete tumor regression and increased survival. Conclusions: Overall, this study not only identifies LT-171-861 as a potent FLT3 inhibitor, but also provides a rationale for the upcoming clinical trial of LT-171-861 in patients with AML and FLT3-ITD mutations.
登录
查看更多内容
影响因子：
2.1
作者：
Grunwald, Michael R.;Levis, Mark J.
通讯作者：
Levis, Mark J.
影响因子：
9.8
作者：
Hu W;Wang T;Wang X;Han J
通讯作者：
Han J
影响因子：
168.9
作者：
Short, Nicholas J.;Rytting, Michael E.;Cortes, Jorge E.
通讯作者：
Cortes, Jorge E.
影响因子：
11.4
作者：
通讯作者：
--
影响因子：
20.3
作者：
DeAngelo, Daniel J.;Stone, Richard M.;Heinrich, Michael C.
通讯作者：
Heinrich, Michael C.